|
Palmetto Pharmaceuticals is a drug development company recently formed
from the leveraged purchase of substantially all of the assets of eNOS
Pharmaceuticals of Cambridge,MA and certain intellectual property
assets of Angiogenix,Inc of San Francisco,CA. These two companies had
done extensive pre-clinical and clinical work on the development of
combination therapies that addressed the improved endothelial function
and enhanced blood flow resulting when the amino acid L-arginine was
administered with statins.
Palmetto Pharmaceuticals has been able to take the data developed
over the past decade and formulate a clinical strategy that neither
eNOS nor Angiogenix was able to pursue because of competitive IP
positions and incomplete understanding of the entire body of data and
intellectual property that collectively had been developed. Palmetto
has acquired the the key assets from each company and is in a position
to exploit the resulting synergy with a clear,concise clinical plan
that addresses the $30 billion lipid management market. We have shown
the the combination of our sustained release L-arginine and statin
significantly reduces triglycerides beyond that by statin alone, and
have exceptional intellectual property protection.
If you have any questions please feel free to contact us at:
  For Business Inquiries - eyal@palmettopharm.com
For Technical and Science Inquires - eyal@palmettopharm.com
|
